Leigh Zawel - 23 Aug 2021 Form 4/A - Amendment Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Officer
Signature
/s/ Jeffrey Trigilio, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
23 Aug 2021
Net transactions value
-$815,422
Form type
4/A - Amendment
Filing time
26 Aug 2021, 19:14:45 UTC
Date Of Original Report
24 Aug 2021
Previous filing
26 Aug 2021
Next filing
08 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Sale $815,422 -28,118 -23% $29.00 93,524 23 Aug 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.60 to $29.26. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

Chief Scientific Officer, Small Molecules This amended Form 4 is being filed to include an explanatory note that the reported sales were made pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021.